Genovis Q1 2025: Interesting outlook but limited near-term visibility - Redeye

Redeye updates its outlook on Genovis following a Q1 report coming in slightly above our estimates across the board. The enzyme business marked its strongest sales to date (excluding licensing). Although limited visibility continues to weigh on the share price, Genovis' expanding cash position presents an interesting outlook.

Länk till analysen i sin helhet: https://www.redeye.se/research/1107296/genovis-q1-2025-interesting-outlook-but-limited-near-term-visibility?utm_source=finwire&utm_medium=RSS